Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of...
- Kevin Norrett appointed Chief Business Officer – - William D. Turner appointed Chief Regulatory and Technical Operations Officer – VANCOUVER, BC, Aug. 6, 2020 /CNW/ - Sierra Oncology, Inc....
- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - - Updated analyses comparing symptomatic benefits of momelotinib to ruxolitinib from the SIMPLIFY-1...
View all news releases
Corporate Presentation Q3 2020
View All Presentations
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts